Hualan Biological Vaccine Inc. (SHE:301207)

Market Cap	12.61B +35.0%
Revenue (ttm)	1.20B +7.8%
Net Income	187.51M -6.1%
EPS	0.32 -5.8%
Shares Out	595.00M
PE Ratio	67.25
Forward PE	58.86
Dividend	1.60 (7.55%)
Ex-Dividend Date	Oct 27, 2025

Volume	20,813,427
Average Volume	5,711,903
Open	20.00
Previous Close	19.63
Day's Range	20.00 - 21.30
52-Week Range	15.78 - 27.88
Beta	0.69
RSI	65.06
Earnings Date	Apr 27, 2026

About Hualan Biological Vaccine

Hualan Biological Vaccine Inc. engages in the research and development, production, and sale of vaccines and genetically engineered biological products in China. The company’s main products include influenza virus split vaccine, quadrivalent influenza virus split vaccine, quadrivalent influenza virus split vaccine (pediatric formulation), H1N1 influenza A virus split vaccine, ACYW135 group meningococcal polysaccharide vaccine, recombinant hepatitis B vaccine (Hansenula polymorpha), group A and C meningococcal polysaccharide vaccine, freeze-drie...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2005
• Employees: 708
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 301207

Financial Performance

In 2025, Hualan Biological Vaccine's revenue was 1.20 billion, an increase of 6.62% compared to the previous year's 1.13 billion. Earnings were 182.92 million, a decrease of -10.99%.